Syngeneic Tumor Models

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Our syngeneic tumor models can be offered as subcutaneous or orthotopic in mice and rats.  Mouse-derived tumor cell models  involve implantation of commercially available tumor cell lines  into mice of the same genetic background to conduct in vivo efficacy evaluation of potential cancer therapies, including targeted therapy, cytotoxic drugs, antibody therapies, and viral therapies.

Compared to xenograph tumor models, syngeneic models have the advantage that tumors grow in the context of an intact immune system.  Therefore they are appropriate models to study agents that act on the host immune system to enhance tumor immunity such as checkpoint inhibitors (e.g anti-CTLA4, anti-PD-1, anti-PD-L1 as illustrated below).  However, because the animals have an intact immune system, they can only be used with rodent-derived tumors and are not suitable for human-derived tumors.

Examples of mouse syngeneic tumor models that Melior has validated include:

      • Breast Cancer – EMT6 Cells
      • Colorectal – CT26.WT Cells
      • Fibrosarcoma – WEHI164 Cells
      • Leukemia – L120 Cells
      • Lung Cancer – LLC Cells
      • Melanoma – B16F10 Cells
      • Pancreatic – KPCY Cells

  • Immune Checkpoint Inhibitor and Chemotherapy Validation of CT26.WT Tumors.   1 x106 CT26.WT mouse colon cancer cells were subcutaneously injected into the rear flank of Balb/c mice. Once mean tumor size reached 100-150mm3, mice were randomized into groups and treated with vehicle, anti-PD-1 antibody (12.5 mg/kg IP) once per week, or paclitaxel (20 mg/kg IP) once per week. Tumor growth volume was monitored at baseline and at days 4, 7 and 11, following initiation of treatment, using calipers.  (Data area mean ± SEM; n=6 for Vehicle and anti-PD-1; n=4 for paclitaxel).

Standard subcutaneous models are an efficient choice for the determination of the response of tumors to a new drug. Tumor cells are implanted into the flank of mice, and tumor growth is monitored by measuring the volume. Subcutaneous tumor implantation allows for efficient growth of tumors for a variety of analyses such as the impact of drugs on tumor growth, animals survival, and further endpoint analyses such as flow cytometry, expression analysis, histology, and more.

Orthotopic models involve seeding tumor cell lines into the corresponding tissue in animal models. This strategy allows for the assessment of tumor development in a relevant environment and efficacy evaluation of potential cancer therapies in a preclinical tumor model that mimics the disease process in humans. With orthotopic models, we can closely monitor and accurately quantify primary tumor growth, metastatic activity, and response to therapy scenarios.

Our syngeneic tumor models are excellent for evaluating novel immunotherapeutic agents and combination therapies.